Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

465
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
465
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

469
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
469
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

232
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
232
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

247
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
247
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

196
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
196
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

452
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
452

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Zearalenone Induces Gap Junction Damage in Ovine Ovarian Granulosa Cells by Upregulating GPR30 and Activating the Oxidative Stress-NLRP3 Inflammasome Axis.

Biomolecules·2026
Same author

Developing a quality evaluation indicator system for lung cancer diagnosis and treatment: a modified Delphi method study.

BMC cancer·2026
Same author

Ethyl acetate fraction of Chaidangbo prescription (EAFC) improves hippocampal neural plasticity in CUMS mice: involving glucocorticoid receptors and Akt-related signaling pathway.

Phytomedicine : international journal of phytotherapy and phytopharmacology·2026
Same author

Personalized infliximab rescue therapy to maximize colectomy-free survival in patients with acute severe ulcerative colitis.

Journal of Crohn's & colitis·2026
Same author

Assessment of High Throughput Sequencing Quality of Host DNA Enriched From Faeces: A Case From Captive Tiger.

Molecular ecology resources·2026
Same author

The Need for Clinical Trial Dataset Specifications to Support Clinical Pharmacology Review of Immunogenicity.

The AAPS journal·2026

Related Experiment Video

Updated: Jan 10, 2026

An HS-MRM Assay for the Quantification of Host-cell Proteins in Protein Biopharmaceuticals by Liquid Chromatography Ion Mobility QTOF Mass Spectrometry
11:09

An HS-MRM Assay for the Quantification of Host-cell Proteins in Protein Biopharmaceuticals by Liquid Chromatography Ion Mobility QTOF Mass Spectrometry

Published on: April 17, 2018

10.6K

Pharmacokinetics and Exposure-Response During Infliximab Induction Therapy in Pediatric IBD Using Point-of-Care

Amy Hemperly1, Jincheng Yang2, Anh Ta2

  • 1Department of Pediatric Gastroenterology, University of California San Diego, La Jolla, San Diego, CA 92093, USA.

Journal of Clinical Medicine
|November 27, 2025
PubMed
Summary

This study analyzed infliximab pharmacokinetics in pediatric inflammatory bowel disease (IBD) patients. Higher drug levels during induction correlated with better outcomes, and weight and albumin impacted clearance, supporting point-of-care testing.

Keywords:
infliximabpediatricpharmacokinetic model

More Related Videos

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

18.2K
Forskolin-induced Swelling in Intestinal Organoids: An In Vitro Assay for Assessing Drug Response in Cystic Fibrosis Patients
07:04

Forskolin-induced Swelling in Intestinal Organoids: An In Vitro Assay for Assessing Drug Response in Cystic Fibrosis Patients

Published on: February 11, 2017

20.0K

Related Experiment Videos

Last Updated: Jan 10, 2026

An HS-MRM Assay for the Quantification of Host-cell Proteins in Protein Biopharmaceuticals by Liquid Chromatography Ion Mobility QTOF Mass Spectrometry
11:09

An HS-MRM Assay for the Quantification of Host-cell Proteins in Protein Biopharmaceuticals by Liquid Chromatography Ion Mobility QTOF Mass Spectrometry

Published on: April 17, 2018

10.6K
In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

18.2K
Forskolin-induced Swelling in Intestinal Organoids: An In Vitro Assay for Assessing Drug Response in Cystic Fibrosis Patients
07:04

Forskolin-induced Swelling in Intestinal Organoids: An In Vitro Assay for Assessing Drug Response in Cystic Fibrosis Patients

Published on: February 11, 2017

20.0K

Area of Science:

  • Pharmacology
  • Pediatric Gastroenterology
  • Immunology

Background:

  • Infliximab (IFX) therapeutic failure during induction is a clinical challenge in pediatric inflammatory bowel disease (IBD).
  • Population pharmacokinetic (PopPK) and exposure-response (ER) analyses are crucial for optimizing IFX therapy in children.
  • Understanding IFX pharmacokinetics is essential for effective IBD management.

Purpose of the Study:

  • To conduct population pharmacokinetic and exposure-response analyses of infliximab in pediatric IBD patients during induction therapy.
  • To identify factors influencing infliximab pharmacokinetics and their association with treatment efficacy.
  • To evaluate the performance of point-of-care (POC) infliximab assays compared to standard ELISA methods.

Main Methods:

  • Prospective, single-center observational study of anti-TNF-naïve pediatric IBD patients (<21 years) receiving infliximab.
  • Nonlinear mixed-effects modeling for PopPK analysis using ELISA-measured serum infliximab levels.
  • Exposure-response analysis correlating infliximab concentrations with efficacy outcomes at week 14.
  • Comparison of infliximab serum levels measured by ELISA and POC assays (RIDA®QUICK IFX/SCAN II).

Main Results:

  • Typical infliximab clearance was 0.252 L/day in a 51 kg pediatric IBD patient; Vc was 3.43 L and Vp was 2.11 L.
  • Patient weight and serum albumin were significant covariates affecting infliximab clearance.
  • Higher infliximab concentrations during induction showed a trend towards improved clinical and biochemical remission at week 14, though not statistically significant due to sample size.
  • High concordance (CCC=0.905) between ELISA and POC infliximab assays was observed.

Conclusions:

  • Parameter estimates for infliximab induction therapy in pediatric IBD patients were established.
  • Weight and albumin are key covariates influencing infliximab clearance, informing individualized dosing strategies.
  • ELISA and POC assays demonstrated comparable results, supporting the utility of POC testing for real-time therapeutic drug monitoring in pediatric IBD.